| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $43,950 | 1 | 33 |
Sells | $5,696 | 2 | 67 |
| Shannon James Samuel | director | 1 | $43,950 | 0 | $0 | $43,950 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | 0 | $0 | 1 | $1,174 | $-1,174 |
| Frankenfield Christopher James | Chief Financial Officer | 0 | $0 | 1 | $4,522 | $-4,522 |
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously …
Over the last 12 months, insiders at Xilio Therapeutics, Inc. have bought $43,950 and sold $5,696 worth of Xilio Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Xilio Therapeutics, Inc. have bought $681,511 and sold $6,184 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Shannon James Samuel (director) — $43,950.
The last purchase of 5,000 shares for transaction amount of $43,950 was made by Shannon James Samuel (director) on 2026‑03‑26.
| 2026-03-26 | Shannon James Samuel | director | 5,000 0.0965% | $8.79 | $43,950 | +1.84% | ||
| 2026-01-02 | Sale | Frankenfield Christopher James | Chief Financial Officer | 7,030 0.0135% | $0.64 | $4,522 | -8.83% | |
| 2026-01-02 | Sale | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | 1,826 0.0035% | $0.64 | $1,174 | -8.83% | |
| 2025-06-17 | Shannon James Samuel | director | 25,000 0.05% | $0.69 | $17,215 | -0.32% | ||
| 2025-06-16 | Russo Rene | PRESIDENT AND CEO | 36,289 0.0695% | $0.68 | $24,680 | -3.23% | ||
| 2025-06-16 | Shannon James Samuel | director | 45,000 0.0869% | $0.69 | $30,870 | -3.23% | ||
| 2025-01-02 | Sale | Frankenfield Christopher James | Chief Financial Officer | 6,954 0.0147% | $0.98 | $6,841 | -30.84% | |
| 2025-01-02 | Sale | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | 1,803 0.0038% | $0.98 | $1,774 | -30.84% | |
| 2024-12-18 | GILEAD SCIENCES, INC. | 10 percent owner | 1.76M 4.8987% | $1.04 | $1.83M | -13.44% | ||
| 2024-04-02 | GILEAD SCIENCES, INC. | 10 percent owner | 485,250 0.9047% | $0.76 | $368,790 | -35.81% | ||
| 2024-02-08 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 1,000 0.0034% | $0.64 | $640 | +57.38% | |
| 2024-01-12 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 2,100 0.0088% | $0.83 | $1,743 | +25.17% | |
| 2024-01-11 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 2,135 0.0083% | $0.87 | $1,857 | +14.46% | |
| 2021-12-10 | Bain Capital Life Sciences Investors, LLC | 10 percent owner | 25,000 0.0858% | $9.65 | $241,202 | -70.24% | ||
| 2021-12-09 | Bain Capital Life Sciences Investors, LLC | 10 percent owner | 4,011 0.0145% | $9.84 | $39,485 | -69.23% | ||
| 2021-12-08 | Bain Capital Life Sciences Investors, LLC | 10 percent owner | 13,458 0.0484% | $9.62 | $129,474 | -68.51% | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP | 10 percent owner | 312,500 1.1398% | $16.00 | $5M | -76.08% | ||
| 2021-10-26 | RiverVest Venture Fund IV, L.P. | 10 percent owner | 250,000 0.9119% | $16.00 | $4M | -76.08% | ||
| 2021-10-26 | Rock Springs Capital Management LP | 10 percent owner | 500,000 1.8238% | $16.00 | $8M | -76.08% | ||
| 2021-10-26 | Flynn James E | 10 percent owner | 387,500 1.4134% | $16.00 | $6.2M | -76.08% |
| Shannon James Samuel | director | 10000 0.152% | $86,800.00 | 3 | 0 | <0.0001% |
| GILEAD SCIENCES, INC. | 10 percent owner | 9105451 138.3775% | $79.04M | 2 | 0 | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2805413 42.6345% | $24.35M | 3 | 0 | <0.0001% |
| SV7 Impact Medicine Fund LP | 10 percent owner | 1613632 24.5227% | $14.01M | 1 | 0 | <0.0001% |
| RiverVest Venture Fund IV, L.P. | 10 percent owner | 1441444 21.9059% | $12.51M | 1 | 0 | <0.0001% |
| Rock Springs Capital Management LP | 10 percent owner | 1256472 19.0949% | $10.91M | 1 | 0 | <0.0001% |
| Flynn James E | 10 percent owner | 1143972 17.3852% | $9.93M | 1 | 0 | <0.0001% |
| BAY CITY CAPITAL LLC | 10 percent owner | 1129490 17.1651% | $9.8M | 1 | 0 | <0.0001% |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 734546 11.1631% | $6.38M | 1 | 3 | <0.0001% |
| Russo Rene | PRESIDENT AND CEO | 281172 4.273% | $2.44M | 1 | 0 | <0.0001% |
$5,831,763 | 118 | -33.78% | $66.68M | |
$17,525,882 | 60 | 5.22% | $64.7M | |
$103,288,323 | 51 | 4.78% | $56.52M | |
$19,705,388 | 47 | 86.26% | $67.15M | |
$24,478,755 | 37 | -34.59% | $53.59M |
| Increased Positions | 16 | +36.36% | 20M | +98.53% |
| Decreased Positions | 14 | -31.82% | 1M | -5.46% |
| New Positions | 11 | New | 17M | New |
| Sold Out Positions | 9 | Sold Out | 892,665 | Sold Out |
| Total Postitions | 46 | +4.55% | 40M | +93.07% |
| Gilead Sciences, Inc. | $6,119.00 | 17.18% | 9.11M | 0 | 0% | 2025-09-30 |
| Bain Capital Life Sciences Investors, Llc | $3,069.00 | 8.62% | 4.57M | 0 | 0% | 2025-09-30 |
| Merck & Co., Inc. | $997.00 | 2.8% | 1.48M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $844.00 | 2.37% | 1.26M | +104,669 | +9.09% | 2025-09-30 |
| Morgan Stanley | $646.00 | 1.82% | 961,917 | -482,409 | -33.4% | 2025-09-30 |
| Aju Ib Investment Co., Ltd. | $449.00 | 1.26% | 667,742 | 0 | 0% | 2025-09-30 |
| Fmr Llc | $344.00 | 0.97% | 511,820 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $221.00 | 0.62% | 328,972 | -40,688 | -11.01% | 2025-09-30 |
| Squarepoint Ops Llc | $221.00 | 0.62% | 328,794 | +93,338 | +39.64% | 2025-09-30 |
| Trustees Of Columbia University In The City Of New York | $168.00 | 0.47% | 249,635 | 0 | 0% | 2025-09-30 |